Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company’s current portfolio is comprised of topical treatments with potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology. The Company’s lead product candidate, ARQ-151 (topical roflumilast cream), is a topical cream formulation of roflumilast, which is a highly potent and selective phosphodiesterase type 4, or PDE4, inhibitor. ARQ-151 is being developed for the treatment of plaque psoriasis, including psoriasis in intertriginous regions such as the groin, axillae, and inframammary areas, as well as atopic dermatitis.